1.0樂天醫藥 - Rakuten Medicalhttps://rakuten-med.com/twRM-1929 光免疫療法治療復發性頭頸部鱗狀細胞癌患者的 1/2a 期研究數據發表於 Head and Neck期刊 - 樂天醫藥 - Rakuten Medicalrich600338<blockquote class="wp-embedded-content" data-secret="zB7UTut89V"><a href="https://rakuten-med.com/tw/news/press-releases/2021/10/28/7499/">RM-1929 光免疫療法治療復發性頭頸部鱗狀細胞癌患者的 1/2a 期研究數據發表於 Head and Neck期刊</a></blockquote><iframe sandbox="allow-scripts" security="restricted" src="https://rakuten-med.com/tw/news/press-releases/2021/10/28/7499/embed/#?secret=zB7UTut89V" width="600" height="338" title="“RM-1929 光免疫療法治療復發性頭頸部鱗狀細胞癌患者的 1/2a 期研究數據發表於 Head and Neck期刊” — 樂天醫藥 - Rakuten Medical" data-secret="zB7UTut89V" frameborder="0" marginwidth="0" marginheight="0" scrolling="no" class="wp-embedded-content"></iframe><script type="text/javascript">
/* <![CDATA[ */
/*! This file is auto-generated */
!function(d,l){"use strict";l.querySelector&&d.addEventListener&&"undefined"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!/[^a-zA-Z0-9]/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret="'+t.secret+'"]'),o=l.querySelectorAll('blockquote[data-secret="'+t.secret+'"]'),c=new RegExp("^https?:$","i"),i=0;i<o.length;i++)o[i].style.display="none";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute("style"),"height"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):"link"===t.message&&(r=new URL(s.getAttribute("src")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener("message",d.wp.receiveEmbedMessage,!1),l.addEventListener("DOMContentLoaded",function(){for(var e,t,s=l.querySelectorAll("iframe.wp-embedded-content"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute("data-secret"))||(t=Math.random().toString(36).substring(2,12),e.src+="#?secret="+t,e.setAttribute("data-secret",t)),e.contentWindow.postMessage({message:"ready",secret:t},"*")},!1)))}(window,document);
//# sourceURL=https://rakuten-med.com/tw/wp-includes/js/wp-embed.min.js
/* ]]> */
</script>
【美國加州聖馬特奧訊】樂天醫藥宣布RM-1929 光免疫療法治療局部復發性頭頸部鱗狀細胞癌 (rHNSCC) (即RM-1929-101臨床試驗, ClinicalTrials.gov 識別碼:NCT02422979) 的 1/2a 期、開放式、多中心研究的數據已獲得 Head and Neck 國際期刊接受並於2021 年 10 月 9 日於線上發表。 該期刊論文描述了這項兩階段研究的設計與結果，旨在闡明 RM-1929 光免疫療法對局部復發性頭頸部鱗狀細胞癌患者的建議劑量、安全性、藥物動力學、致免疫原性和初步療效。研究的第一階段*（劑量遞增）確定了 RM-1929 的建議藥物劑量為 […]https://rakuten-med.com/tw/wp-content/uploads/sites/11/2021/02/RakutenMedical_KV.png1500900